Promising biomarkers for predicting the outcomes of patients with KRAS wild-type metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: A systematic review with meta-Analysis

International Journal of Cancer

Volumn 133, Issue 8, 2013, Pages 1914-1925

  Yang, Zu Yao ^a   Wu, Xin Yin ^a   Huang, Ya Fang ^a   Di, Meng Yang ^a   Zheng, Da Yong ^b   Chen, Jin Zhang ^b   Ding, Hong ^b   Mao, Chen ^a,c   Tang, Jin Ling ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

biomarker; colorectal cancer; KRAS; meta Analysis; monoclonal antibody

Indexed keywords

B RAF KINASE; BEVACIZUMAB; BIOLOGICAL MARKER; CAPECITABINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; UFT;

ARTICLE; BRAF GENE; CANCER PROGNOSIS; GENE; GENE MUTATION; HUMAN; METASTATIC COLORECTAL CANCER; ONCOGENE K RAS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PIK3CA GENE; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; WILD TYPE;

BIOMARKER; COLORECTAL CANCER; KRAS; META-ANALYSIS; MONOCLONAL ANTIBODY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; PTEN PHOSPHOHYDROLASE; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84881543270     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28153     Document Type: Article

References (51)

1. GLOBOCAN. Cancer fact sheet. 2008. Available at: http://globocan.iarc.fr/ factsheets/cancers/colorectal.asp#INCIDENCE1. Accessed on May 14, 2012.
2. Sargent DJ, Wieand HS, Haller DG, et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 2005; 23: 8664-70.
3. Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009; 27: 663-71.
4. Tol J, Punt CJ,. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review. Clin Ther 2010; 32: 437-53.
5. Van Cutsem E, Köhne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-17.
6. Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010; 28: 4697-705.
7. Peeters M, Price TJ, Cervantes A, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared to FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2010; 28: 4706-13.
8. Sobrero AF, Maurel J, Fehrenbacher L, et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 2311-9.
9. Schrag D,. The price tag on progress-chemotherapy for colorectal cancer. N Engl J Med 2004; 351: 317-9.
10. Bardelli A, Siena S,. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 2010; 28: 1254-61.
11. Di Fiore F, Sesboue R, Michel P, et al. Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer. Br J Cancer 2010; 103: 1765-72.
12. Sartore-Bianchi A, Bencardino K, Di Nicolantonio F, et al. Integrated molecular dissection of the epidermal growth factor receptor (EFGR) oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer. Targ Oncol 2010; 5: 19-28.
13. Rajagopalan H, Bardelli A, Lengauer C, et al. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002; 418: 934.
14. Dahabreh IJ, Terasawa T, Castaldi PJ, et al. Systematic review: anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer. Ann Intern Med 2011; 154: 37-49.
15. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 2007; 67: 2643-8.
16. Sartore-Bianchi A, Di Nicolantonio F, Nichelatti M, et al. Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS One 2009; 4: e7287.
17. Van Cutsem E, Köhne CH, Láng I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011; 29: 2011-9.
18. De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010; 11: 753-62.
19. Frattini M, Saletti P, Romagnani E, et al. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 2007; 97: 1139-45.
20. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-Analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009; 339: b2700.
21. Deeks JJ, Higgins JPT, Altman DG, eds. Analysing and presenting results. In:, Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions 4.2.6. Chichester, UK: Wiley, 201-44.
22. DerSimonian R, Laird N,. Meta-Analysis in clinical trials. Control Clin Trials 1986; 7: 177-88.
23. Higgins JPT, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-Analyses. BMJ 2003; 327: 557-60.
24. Borenstein M, Hedges LV, Higgins JPT, et al. Power analysis for meta-Analysis. In:, Borenstein M, Hedges LV, Higgins JPT, et al., eds. Introduction to meta-Analysis. Chichester, UK: Wiley, 2009: 257-76.
25. Egger M, Smith DG, Schneider M, et al. Bias in meta-Analysis detected by a simple, graphical test. BMJ 1997; 315: 629-34.
26. Di Nicolantonio F, Martini M, Molinari F, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008; 26: 5705-12.
27. Laurent-Puig P, Cayre A, Manceau G, et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 2009; 27: 5924-30.
28. Li F,. Impact of KRAS mutation and PTEN protein expression on survival of Chinese metastatic colorectaI cancer patients treated with cetuximab. Master Degree thesis, Sun Yat-Sen University, 2009.
29. Loupakis F, Pollina L, Stasi I, et al. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol 2009; 27: 2622-9.
30. Loupakis F, Ruzzo A, Cremolini C, et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer 2009; 101: 715-21.
31. Moroni M, Veronese S, Benvenuti S, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005; 6: 279-86.
32. Perrone F, Lampis A, Orsenigo M, et al. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol 2009; 20: 84-90.
33. Rebersek M, Ocvirk J, Boc M, et al. Correlation of BRAF status with clinical response to cetuximab in KRAS wild type (KRAS WT) metastatic colorectal (MCRC) patients-Single institution experience. Ann Oncol 2010; 21: viii 216. Proceedings of 35th ESMO Congress;08-12 October 2010; Milan, Italy.
34. Saridaki Z, Tzardi M, Papadaki C, et al. Impact of KRAS, BRAF, PIK3CA Mutations, PTEN, AREG, EREG expression and skin rash in > = 2nd line cetuximab- based therapy of colorectal cancer patients. PLoS One 2011; 6: e15980.
35. Tol J, Dijkstra JR, Klomp M, et al. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. Eur J Cancer 2010; 46: 1997-2009.
36. Wong NS, Fernando NH, Nixon AB, et al. A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer. Anticancer Res 2011; 31: 255-61.
37. Bokemeyer C, Cutsem EV, Rougier P, et al. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer 2012; 48: 1466-75.
38. Inno A, Di Salvatore M, Cenci T, et al. Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer? Clin Colorectal Cancer 2011; 10: 325-32.
39. Lin JK, Lin AJ, Lin CC, et al. The status of EGFR-Associated genes could predict the outcome and tumor response of chemo-refractory metastatic colorectal patients using cetuximab and chemotherapy. J Surg Oncol 2011; 104: 661-6.
40. Modest DP, Jung A, Moosmann N, et al. The influence of KRAS and BRAF mutations on the efficacy of cetuximab-based first-line therapy of metastatic colorectal cancer: an analysis of the AIO KRK-0104-trial. Int J Cancer 2012; 131: 980-6.
41. Park JH, Han SW, Oh DY, et al. Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer. Cancer Chemother Pharmacol 2011; 68: 1045-55.
42. Sood A, McClain D, Maitra R, et al. PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer. Clin Colorectal Cancer 2012; 11: 143-50.
43. Lau J, Ioannidis JP, Terrin N, et al. The case of the misleading funnel plot. BMJ 2006, 333: 597-600.
44. FDA. Erbitux (cetuximab) label. Available at: www.accessdata.fda.gov/ drugsatfda-docs/label/2009/125084s168lbl.pdf. Accessed on May 14, 2012.
45. FDA. Vectibix (panitumumab). Available at: http://www.accessdata.fda.gov/ drugsatfda-docs/label/2009/125147s080lbl.pdf. Accessed on March 25, 2011.
46. European Medicines Agency website, European Public Assessment Report. Available at: http://www.emea.europa.eu/docs/en-GB/document-library/Medicine-QA/ 2009/12/WC500017035.pdf. Accessed on July 19, 2012.
47. European Medicines Agency website, European Public Assessment Report. Available at: http://www.emea.europa.eu/docs/en-GB/document-library/Summary-of- opinion/human/000558/WC500059827.pdf. Accessed on July 19, 2012.
48. Zhao L, Vogt PK,. Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc Natl Acad Sci U S A 2008; 105: 2652-7.
49. Yang ZY, Shen WX, Hu XF, et al. EGFR gene copy number as a predictive biomarker for the treatment of metastatic colorectal cancer with anti-EGFR monoclonal antibodies: a meta-Analysis. J Hematol Oncol 2012; 5: 52.
50. Perkins G, Lièvre A, Ramacci C, et al. Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to anti-EGFR antibodies in colorectal cancer. Int J Cancer 2010; 127: 1321-31.
51. Simon RM, Paik S, Hayes DF,. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 2009; 101: 1446-52.